Report : Asia Pacific Upstream Bioprocessing Market Forecast to 2030 - Regional analysis - by Product Type (Bioreactors/Fermenters, Cell Culture, Filters, Bags and Containers, and Others), Workflow (Media Preparation, Cell Culture, and Cell Separation), Usage Type (Single-use and Multi-use), and Mode (In-house and Outsourced)
At 14.1% CAGR, Asia Pacific Upstream Bioprocessing Market is Projected to be Worth US$ 5,678.99 Million by 2030, says Business Market Insights.
According to Business Market Insights' research, the Asia Pacific upstream bioprocessing market was valued at US$ 1,976.10 million in 2022 and is expected to reach US$ 5,678.99 million by 2030, registering a CAGR of 14.1% from 2022 to 2030. Outsourcing of biopharmaceutical manufacturing and Technological advancements are among the critical factors attributed to the Asia Pacific upstream bioprocessing market expansion.
A large number of contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs) are engaging in bioprocessing activities, which triggers the demand for bioreactors in these facilities. The strategic outsourcing of pharmaceutical manufacturing through bioprocessing allows biopharmaceutical companies to leverage external partners' expertise and advanced capabilities in upstream processes, facilitating access to specialized technologies, process optimization expertise, and scalable manufacturing capacity. By partnering with CDMOs and CMOs, biopharmaceutical firms can efficiently manage manufacturing needs, accommodate fluctuations in production demands, and focus on core research and development activities. Additionally, outsourcing offers cost efficiencies and risk mitigation by leveraging external partners' established infrastructure and regulatory-compliant facilities. Outsourcing the bioprocessing functions allows biopharmaceutical companies to focus on fostering innovation, technological advancements, and overall upstream process expansion. Thus, the outsourcing of biopharmaceutical manufacturing significantly drives the growth of the upstream bioprocessing market.
On the contrary, stringent regulatory framework hampers the growth of Asia Pacific upstream bioprocessing market.
Based on product type, the Asia Pacific upstream bioprocessing market is segmented into bioreactors/fermenters, cell culture, filters, bags and containers, and others. The bioreactors/fermenters segment held 35.3% market share in 2022, amassing US$ 697.06 million. It is projected to garner US$ 1,983.32 million by 2030 to expand at 14.0% CAGR during 2022-2030.
Based on workflow, the Asia Pacific upstream bioprocessing market is segmented into media preparation, cell culture, and cell separation. The cell separation segment held 41.3% share of Asia Pacific upstream bioprocessing market in 2022, amassing US$ 816.67 million. It is projected to garner US$ 2,426.89 million by 2030 to expand at 14.6% CAGR during 2022-2030.
By usage type, the Asia Pacific upstream bioprocessing market is bifurcated into single-use and multi-use. The single-use segment held 54.8% share of Asia Pacific upstream bioprocessing market in 2022, amassing US$ 1,083.63 million. It is projected to garner US$ 3,168.36 million by 2030 to expand at 14.4% CAGR during 2022-2030.
In terms of mode, the Asia Pacific upstream bioprocessing market is bifurcated into In-house and outsourced. The In-house segment held 57.8% share of Asia Pacific upstream bioprocessing market in 2022, amassing US$ 1,141.91 million. It is projected to garner US$ 3,223.08 million by 2030 to expand at 13.8% CAGR during 2022-2030.
Based on country, the Asia Pacific upstream bioprocessing market has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 30.0% share of Asia Pacific upstream bioprocessing market in 2022. It was assessed at US$ 592.83 million in 2022 and is likely to hit US$ 1,698.92 million by 2030, exhibiting a CAGR of 14.1% during 2022-2030.
Key players operating in the Asia Pacific upstream bioprocessing market are Thermo Fisher Scientific Inc, Esco Micro Pte Ltd, Sartorius AG, Danaher Corp, Getinge AB, Merck KGaA, Corning Inc, and Entegris Inc, among others.
- In March 2021, HyPerforma DynaDrive S.U.B. in different volumes, 3,000 L and 5,000 L models. Thermo Fisher Scientific's largest commercially accessible S.U.B., the first-of-its-size 5,000 L S.U.B., allows biopharmaceutical businesses to incorporate single-use technologies into large-scale bioprocesses, such as cGMP manufacture at very high cell density and perfusion cell culture.
- In December 2023, Merck has acquired Erbi Biosystems, a Massachusetts-based company that developed the "Breez" 2 ml micro-bioreactor platform technology. Merck's upstream therapeutic protein portfolio is boosted by the purchase, enabling it to promptly develop lab-scale protocols for scalable cell-based perfusion bioreactor processes with capacities ranging from 2 ml to 2000 l. Additionally, it offers opportunities for further study and advancement in cutting-edge modality applications, like cell therapies.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com